GlassScriptPhysician profile
Michael A Dawson
NPI 1669401204
$9,419.41
in general payments reported to CMS, 2019-2025
15 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $179 · 2021: $60.75 · 2022: $18.46 · 2023: $5,143 · 2024: $3,514 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,002 · Travel and Lodging: $1,252 · Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,002.00 |
| Travel and Lodging | $1,251.54 |
| Food and Beverage | $536.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,808.61 | 2022-2025 | Jada System |
| Abbvie INC. | $224.76 | 2019-2021 | |
| Coopersurgical, INC. | $66.72 | 2019-2020 | |
| Lupin INC. | $59.35 | 2019-2020 | |
| Duchesnay USA Incorporated | $35.78 | 2019 | |
| Avion Pharmaceuticals | $35.13 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $30.90 | 2019-2020 | |
| Exeltis, USA INC. | $29.91 | 2019-2020 | |
| Allergan, INC. | $26.19 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.20 | 2019-2020 | |
| Alydia Health | $18.85 | 2021 | |
| Merck Sharp & Dohme LLC | $15.73 | 2019 | |
| Gilead Sciences, INC. | $15.31 | 2019 | |
| Aspira Women'S Health INC | $15.23 | 2020 | |
| Hologic Sales and Service, LLC | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.